<DOC>
	<DOCNO>NCT00844233</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy Irinotecan Bead neoadjuvant treatment ( i.e . Irinotecan Bead administer prior surgery ) resectable liver metastases colorectal cancer .</brief_summary>
	<brief_title>Study Chemoembolisation Using Irinotecan Bead Prior Surgery Metastatic Colorectal Cancer</brief_title>
	<detailed_description>The Primary Endpoint study Tumour resectability surgery . Secondary Endpoints : 1 . Safety assess SAE AE monitoring ( NCI CTCAE v3.0 ) 2 . Tumour response assess imaging ( RECIST necrosis ) 3 . Viable residual tumour assess pathological evaluation resect liver tissue . 4 . Recurrence ( time site ) follow resection 5 . Correlation tumour response image pathology</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Inclusion criterion 1 . Presence potentially resectable colorectal cancer liver metastasis , le 60 % liver tumour replacement . The consult surgeon , accord local practice , determine resectability . 2 . Patients undergone complete resection primary tumour without gross microscopic evidence residual disease ( R0 ) , primary tumour consider R0 resectable screening . 3 . Age : 1880 year . 4 . ECOG Status ≤2 . 5 . No previous irinotecancontaining chemotherapy advance disease . 6 . Previous chemotherapy allow ( unless contain irinotecan ) , must end least one month prior study entry . 7 . Presence adequate contraception fertile ( M/F ) patient . Pregnant lactate woman exclude . 8 . Absence previous malignancy adequately treat situ carcinoma cervix nonmelanoma skin cancer ( unless diseasefree interval least 10 year ) . 9 . Patients participate another clinical trial investigational drug 30 day prior enrolment . 10 . Absence : Peripheral neuropathy ( CTC &gt; grade 1 ) Uncontrolled congestive heart failure angina pectoris , hypertension arrhythmia . History significant neurologic psychiatric disorder Active infection 11 . Written inform consent accord ICH/EU GCP , applicable local , national international regulation . 12 . Patients liverdominant disease , define ≥80 % tumour body burden confine liver . Unilobar disease , bilobar disease suitable treatment single chemoembolisation procedure , maximum 4 lesion . 13 . Hematologic function : WBC ≥3.0 x 10*9/L , platelet ≥100 x 10*9/L , Absolute neutrophil count &gt; 1.5 x 10*9/l . 14 . Adequate organ function measure : 1 . Serum creatinine ≤2 x upper limit normal ( ULN ) . 2 . Serum transaminase ( AST &amp; ALT ) ≤5 x ULN . 3 . Total bilirubin ≤1.5 x ULN . 4 . Prothrombin time &gt; 50 % normal . Exclusion criteria 1 . Extrahepatic metastasis constitute &gt; 20 % tumour body burden . 2 . Contraindications irinotecan : 1 . Chronic inflammatory bowel disease and/or bowel obstruction . 2 . History severe hypersensitivity reaction irinotecan hydrochloride trihydrate . 3 . Severe bone marrow failure . 4 . Concomitant use St John 's Wort . 3 . Active bacterial , viral fungal infection within 72 hour study entry . 4 . Allergy contrast medium manage standard care . 5 . Any contraindication hepatic embolisation procedure : 1. portosystemic shunt . 2. hepatofugal blood flow . 3. severe atheromatosis . 6 . Contraindication hepatic artery catheterisation , patient severe peripheral vascular disease preclude catheterisation . 7 . Other significant medical surgical condition , medication treatment regimen , would place patient undue risk , would preclude safe use chemoembolisation would interfere study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>